NO20070977L - Dobbel NK1/Nk3 antagonister mot schizofreni - Google Patents
Dobbel NK1/Nk3 antagonister mot schizofreniInfo
- Publication number
- NO20070977L NO20070977L NO20070977A NO20070977A NO20070977L NO 20070977 L NO20070977 L NO 20070977L NO 20070977 A NO20070977 A NO 20070977A NO 20070977 A NO20070977 A NO 20070977A NO 20070977 L NO20070977 L NO 20070977L
- Authority
- NO
- Norway
- Prior art keywords
- noh
- chr
- hydrogen
- lower alkyl
- schizophrenia
- Prior art date
Links
- 201000000980 schizophrenia Diseases 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04103794 | 2004-08-06 | ||
| PCT/EP2005/008144 WO2006013050A1 (fr) | 2004-08-06 | 2005-07-27 | Antagonistes doubles nk1/nk3 contre la schizophrénie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20070977L true NO20070977L (no) | 2007-04-23 |
Family
ID=35045180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20070977A NO20070977L (no) | 2004-08-06 | 2007-02-21 | Dobbel NK1/Nk3 antagonister mot schizofreni |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20060030600A1 (fr) |
| EP (1) | EP1776117A1 (fr) |
| JP (1) | JP2008509103A (fr) |
| KR (1) | KR20070043821A (fr) |
| CN (1) | CN101035533B (fr) |
| AR (1) | AR050282A1 (fr) |
| AU (1) | AU2005268895B2 (fr) |
| BR (1) | BRPI0513084A (fr) |
| CA (1) | CA2575894A1 (fr) |
| IL (1) | IL181048A0 (fr) |
| MX (1) | MX2007001323A (fr) |
| MY (1) | MY148684A (fr) |
| NO (1) | NO20070977L (fr) |
| NZ (1) | NZ552802A (fr) |
| RU (1) | RU2374229C2 (fr) |
| TW (1) | TWI305725B (fr) |
| WO (1) | WO2006013050A1 (fr) |
| ZA (1) | ZA200700820B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007039123A2 (fr) * | 2005-09-22 | 2007-04-12 | Smithkline Beecham Corporation | Traitement combine |
| AU2008240804B2 (en) * | 2007-04-20 | 2013-02-21 | F. Hoffmann-La Roche Ag | Pyrrolidine derivatives as dual NK1/NK3 receptor antagonists |
| GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| WO2011054773A1 (fr) | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Nouveaux composes lactame |
| US8487102B2 (en) * | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
| US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
| US8426450B1 (en) * | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| CA2930008A1 (fr) | 2013-11-08 | 2015-05-14 | Kissei Pharmaceutical Co., Ltd. | Derive de carboxymethylpiperidine |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| SMT201900719T1 (it) | 2015-05-18 | 2020-01-14 | Nerre Therapeutics Ltd | Antagonista del recettore nk-1/nk-3 per il trattamento delle vampate di calore |
| AU2019233606B2 (en) | 2018-03-14 | 2024-10-03 | KaNDy Therapeutics Limited | Novel pharmaceutical formulation comprising dual NK-1/NK-3 receptor antagonists |
| PE20221167A1 (es) | 2019-11-15 | 2022-07-25 | Kandy Therapeutics Ltd | Nuevo proceso quimico para la elaboracion de 6-cloro-4-(4-fluoro-2-metilfenil)piridin-3-amina, un intermediario clave de nt-814 |
| US12533358B1 (en) | 2025-05-14 | 2026-01-27 | Bayer Consumer Care Ag | Methods of treatment with elinzanetant |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972938A (en) * | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
| JP2002517448A (ja) * | 1998-06-11 | 2002-06-18 | メルク シャープ エンド ドーム リミテッド | 精神障害の治療用ｎｋ−１受容体アンタゴニストの使用 |
| PT1035115E (pt) * | 1999-02-24 | 2005-01-31 | Hoffmann La Roche | Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1 |
| TR200102490T2 (tr) * | 1999-02-24 | 2001-12-21 | F.Hoffmann-La Roche Ag | Fenil ve piridinil türevleri |
| GB0017256D0 (en) * | 2000-07-13 | 2000-08-30 | Merck Sharp & Dohme | Therapeutic agents |
| MXPA03000366A (es) * | 2000-07-14 | 2003-05-27 | Hoffmann La Roche | N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina. |
| TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
| TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| SE0003476D0 (sv) * | 2000-09-28 | 2000-09-28 | Astrazeneca Ab | Compounds |
| US6531597B2 (en) * | 2001-02-13 | 2003-03-11 | Hoffmann-La Roche Inc. | Process for preparation of 2-phenyl acetic acid derivatives |
| CA2444395C (fr) * | 2001-04-23 | 2010-12-21 | F. Hoffmann-La Roche Ag | Utilisation d'antagonistes de recepteur de nk-1 contre l'hyperplasie benigne de la prostate |
| US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
| GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| RU2347777C2 (ru) * | 2003-07-03 | 2009-02-27 | Ф.Хоффманн-Ля Рош Аг | Двойные агонисты nk1/nk3 для лечения шизофрении |
-
2005
- 2005-07-26 US US11/189,404 patent/US20060030600A1/en not_active Abandoned
- 2005-07-27 KR KR1020077002847A patent/KR20070043821A/ko not_active Ceased
- 2005-07-27 JP JP2007524233A patent/JP2008509103A/ja active Pending
- 2005-07-27 CN CN2005800338233A patent/CN101035533B/zh not_active Expired - Fee Related
- 2005-07-27 MX MX2007001323A patent/MX2007001323A/es active IP Right Grant
- 2005-07-27 EP EP05769687A patent/EP1776117A1/fr not_active Withdrawn
- 2005-07-27 AU AU2005268895A patent/AU2005268895B2/en not_active Expired - Fee Related
- 2005-07-27 RU RU2007103840/04A patent/RU2374229C2/ru not_active IP Right Cessation
- 2005-07-27 NZ NZ552802A patent/NZ552802A/en not_active IP Right Cessation
- 2005-07-27 WO PCT/EP2005/008144 patent/WO2006013050A1/fr not_active Ceased
- 2005-07-27 BR BRPI0513084-0A patent/BRPI0513084A/pt not_active IP Right Cessation
- 2005-07-27 CA CA002575894A patent/CA2575894A1/fr not_active Abandoned
- 2005-08-03 TW TW094126426A patent/TWI305725B/zh not_active IP Right Cessation
- 2005-08-04 AR ARP050103235A patent/AR050282A1/es unknown
- 2005-08-05 MY MYPI20053652A patent/MY148684A/en unknown
-
2007
- 2007-01-29 IL IL181048A patent/IL181048A0/en unknown
- 2007-01-29 ZA ZA200700820A patent/ZA200700820B/xx unknown
- 2007-02-21 NO NO20070977A patent/NO20070977L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2007103840A (ru) | 2008-09-20 |
| AR050282A1 (es) | 2006-10-11 |
| ZA200700820B (en) | 2009-01-28 |
| JP2008509103A (ja) | 2008-03-27 |
| TWI305725B (en) | 2009-02-01 |
| CA2575894A1 (fr) | 2006-02-09 |
| BRPI0513084A (pt) | 2008-04-22 |
| MX2007001323A (es) | 2007-04-02 |
| CN101035533B (zh) | 2010-05-05 |
| EP1776117A1 (fr) | 2007-04-25 |
| AU2005268895A1 (en) | 2006-02-09 |
| US20060030600A1 (en) | 2006-02-09 |
| IL181048A0 (en) | 2007-07-04 |
| WO2006013050A1 (fr) | 2006-02-09 |
| HK1111340A1 (zh) | 2008-08-08 |
| AU2005268895B2 (en) | 2011-03-17 |
| NZ552802A (en) | 2009-07-31 |
| TW200616630A (en) | 2006-06-01 |
| MY148684A (en) | 2013-05-31 |
| RU2374229C2 (ru) | 2009-11-27 |
| KR20070043821A (ko) | 2007-04-25 |
| CN101035533A (zh) | 2007-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20070977L (no) | Dobbel NK1/Nk3 antagonister mot schizofreni | |
| NO20056007L (no) | Dobbel NK1/NK3 antagonister for behandling av schizofreni | |
| TW200734337A (en) | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | |
| NO20062370L (no) | Amidderivater | |
| ATE353870T1 (de) | Dibenzylaminverbindung und deren medizinische verwendung | |
| NO20072833L (no) | Bi- og tricykliske substituterte fenylmetanoner som glycinetransportor I-(Glyt-1)-inhibitorer for behandling av Alzheimers sykdom | |
| JP2007512299A5 (fr) | ||
| HUP0303164A2 (hu) | Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítmények | |
| NO20033385L (no) | Fuserte heterocykliske forbindelser | |
| MY142807A (en) | Benzimidazole derivative and use thereof. | |
| EA200401381A1 (ru) | 3-гетероарилзамещённые изоксазолины | |
| DE60129806D1 (de) | Neue bizyklische verbindungen | |
| NO20003451L (no) | 2,3-substituerte indolforbindelser som cox-2 inhibitorer | |
| AR037418A1 (es) | Derivados de benzotiazol | |
| NO20053762L (no) | Kondensert furanforbindelse. | |
| EA019037B1 (ru) | 5-[5-[2-[3,5-бис(трифторметил)фенил-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил]-2-алкилпролинамиды в качестве антагонистов рецептора nk1 | |
| PE20061156A1 (es) | Derivados de benzamida como agentes inhibidores del transportador de glicina | |
| NZ519126A (en) | Novel IL-8 receptor antagonists | |
| NO20032291L (no) | Pyrimidinderivater | |
| DK2970210T3 (en) | Pyrazolylbenzo [d] imidazole | |
| DK169239B1 (da) | Pyrrolo[1,2-a][4,1]benzoxazepiner og salte deraf, deres fremstilling og farmaceutiske præparater med indhold deraf | |
| NO20070366L (no) | Fremgangsmate for fremstilling av 3-(4- piperidinyl)-2,3,4,5-tetrahydro-l,3-benzodiazepin -2(1H)-ON | |
| NO20063111L (no) | Fremgangsmate for fremstilling av tiazolpyrimidiner | |
| NO20061831L (no) | Benzofuranderivater av karbamoyltype | |
| TW200700390A (en) | Metabolites for nk-1 antagonists for emesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |